SavedAdd your journal

Journals / Türk Diş Hekimliği Araştırma Dergisi / 2026 / Cilt: 2 Sayı: 1

Immunohistochemical Determination Of Vasoactive Intestinal Peptide(VIP) Levels In Smokers and Non-Smokers Chronic Periodontitis Patients And Periodontal Healthy Individuals

Kronik Periodontitisli, Periodontal Sağlıklı; Sigara İçen/İçmeyen Bireylerde Doku Düzeyinde Vazoaktif İntestinal Peptit(VIP) Seviyelerinin İmmünohistokimyasal Olarak Belirlenmesi

Mustafa Şimşekyılmaz0000-0003-1660-6026
Taner Arabacı(ATATÜRK ÜNİVERSİTESİ, DİŞ HEKİMLİĞİ FAKÜLTESİ)0000-0003-0476-1010
Elif Bilici(ATATÜRK ÜNİVERSİTESİ, SAĞLIK BİLİMLERİ ENSTİTÜSÜ, PERİODONTOLOJİ (DR))0000-0002-9272-5804
Beyza Nur Şahin(ATATÜRK ÜNİVERSİTESİ, DİŞ HEKİMLİĞİ FAKÜLTESİ)0000-0001-7697-6841
Pages
154–162
Publication Date
2023-06-05
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

There is an increase at the level of this protein and its receptor in periodontal tissue when patients has periodontal disease or they are smokers.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: The main aim of this study to investigate the effect of periodontal status and smoking on vasoactive intestinal peptide(VIP) levels on periodontal tissue.
📊
Key Findings & Data:Results: VIP receptor numerical density levels were statistically significant between all groups (p 0.05).
💡
Conclusion & Impact:There is an increase at the level of this protein and its receptor in periodontal tissue when patients has periodontal disease or they are smokers.
🔬Design:Araştırma Makalesi
📍Scope:Comprehensive Sample
⚙️Variables:vazoaktif intestinal peptit · kronik periodontitis · sigara kullanımı

Abstract

Background: The main aim of this study to investigate the effect of periodontal status and smoking on vasoactive intestinal peptide(VIP) levels on periodontal tissue. Material and Method: Patients were divided four groups. Groups were named non-smokers and periodontal healthy individuals(H), smokers and periodontal healthy individuals(HS), non-smokers and chronic periodontitis patients(CP), smokers and chronic periodontitis patients(CPS). Collected periodontal tissue were stained immunohistochemically and then the numerical densities of the VIP(+) cells were determined by steorology method. Results: VIP receptor numerical density levels were statistically significant between all groups (p 0.05). Conclusion: The VIP acts as an anti-inflammatory neuropeptide that affects the cytokines in the pro-inflammatory pathway. There is an increase at the level of this protein and its receptor in periodontal tissue when patients has periodontal disease or they are smokers.

Özet

Amaç: Periodontal durum ve sigara kullanımının vazoaktif intestinal peptit(VIP) seviyelerine etkisini incelemek. Gereç ve Yöntem: Kronik periodontitisli (KP) ve periodontal sağlıklı sigara içen ve içmeyen dört grup oluşturulmuştur. (Sigara kullanımı yok ve periodontal açıdan sağlıklı bireyler:S, Sigara kullanımı var ve periodontal açıdan sağlıklı bireyler:SS, Sigara kullanımı yok ve kronik periodontitisli bireyler:KP, Sigara kullanımı var ve kronik periodontitisli bireyler:KPS). Alınan periodontal dokular immünohistokimyasal olarak boyanmış ve VIP(+) hücrelerin steoroloji yöntemiyle ortalama sayısal yoğunlukları belirlenmiştir. Bulgular: Bütün gruplar arasında VIP reseptör ortalama sayısal yoğunluk seviyelerinde istatistiksel olarak anlamlı fark bulunmuştur (p 0.05). Sonuç: Pro-inflamatuar yolaktaki sitokinleri etkileyen VIP anti-inflamatuar bir nöropeptit olarak çalışmaktadır. Bu proteinde ve reseptöründe, KP ve sigara kullanımı ile periodontal dokulardaki seviyelerinde artış görülmektedir.

🔖

Cite This Article

Şimşekyılmaz, M., Arabacı, T., Bilici, E., Şahin, B. N. (2023). Immunohistochemical Determination Of Vasoactive Intestinal Peptide(VIP) Levels In Smokers and Non-Smokers Chronic Periodontitis Patients And Periodontal Healthy Individuals. Türk Diş Hekimliği Araştırma Dergisi, Cilt: 2 Sayı: 1, 154–162. https://doi.org/10.58711/turkishjdentres.vi.1259516

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (44)

  1. Pihlstrom BL, Michalowicz BS, Johnson NW. Periodontal diseases. The lancet. 2005;366(9499):1809-1820.
  2. Genco RJ, Borgnakke WS. Risk factors for periodontal disease. Periodontol 2000. 2013;62(1):59-94.
  3. Armitage GC. Periodontal diagnoses and classification of periodontal diseases. Periodontol 2000. 2004;34(1):9-21.
  4. Papapanou PN, Sanz M, Buduneli N, et al. Periodontitis: Consensus report of workgroup 2 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J Periodontol. 2018;89:S173-S182.
  5. Armitage GC. Development of a classification system for periodontal diseases and conditions. Ann Periodontol. 1999;4(1):1-6.
  6. Erdemir OE. Sigara ve periodontal hastalık. Published online 2005.
  7. Borojevic T. Smoking and periodontal disease. Mater Socio-Medica. 2012;24(4):274.
  8. Eke PI, Dye BA, Wei L, Thornton-Evans GO, Genco RJ. Prevalence of periodontitis in adults in the United States: 2009 and 2010. J Dent Res. 2012;91(10):914-920.
  9. Kocher T, Schwahn C, Gesch D, et al. Risk determinants of periodontal disease–an analysis of the Study of Health in Pomerania (SHIP 0). J Clin Periodontol. 2005;32(1):59-67.
  10. Kinane DF, Chestnutt IG. Smoking and periodontal disease. Crit Rev Oral Biol Med. 2000;11(3):356-365.
  11. Leite FRM, Nascimento GG, Baake S, Pedersen LD, Scheutz F, López R. Impact of Smoking Cessation on Periodontitis: A Systematic Review and Meta-analysis of Prospective Longitudinal Observational and Interventional Studies. Nicotine Tob Res Off J Soc Res Nicotine Tob. 2019;21(12):1600-1608. doi:10.1093/ntr/nty147
  12. Eminoğlu Dö, Çanakçı V. Evaluation of Oxidative Status in Patients With Chronic Periodontitis and Additional Tobacco Abuse: A Cross-Sectional Study. Atatürk Üniversitesi Diş Hekim Fakültesi Derg. 30(4):536-544.
  13. Alkan EA, Dikilitaş A, Alkan Ö, Parlar A. Sigara ve periodontal hastalık ilişkisi. Acta Odontol Turc. 2013;30(1):49-53.
  14. Pabst MJ, Pabst KM, Collier JA, et al. Inhibition of neutrophil and monocyte defensive functions by nicotine. J Periodontol. 1995;66(12):1047-1055. doi:10.1902/jop.1995.66.12.1047
  15. Graswinckel JEM, Van Der Velden U, Van Winkelhoff AJ, Hoek FJ, Loos BG. Plasma antibody levels in periodontitis patients and controls. J Clin Periodontol. 2004;31(7):562-568.
  16. Güntsch A, Erler M, Preshaw PM, Sigusch BW, Klinger G, Glockmann E. Effect of smoking on crevicular polymorphonuclear neutrophil function in periodontally healthy subjects. J Periodontal Res. 2006;41(3):184-188.
  17. Kanehira T, Shibata K, Kashiwazaki H, Inoue N, Morita M. Comparison of antioxidant enzymes in saliva of elderly smokers and non-smokers. Gerodontology. 2006;23(1):38-42.
  18. Kraal JH, Kenney EB. The response of polymorphonuclear leukocytes to chemotictic stimulation for smokers and nonsmokers. J Periodontal Res. 1979;14(5):383-389.
  19. Boström L, Linder LE, Bergström J. Clinical expression of TNF-alpha in smoking-associated periodontal disease. J Clin Periodontol. 1998;25(10):767-773. doi:10.1111/j.1600-051x.1998.tb02368.x
  20. Victor FC, Gottlieb AB. TNF-alpha and apoptosis: implications for the pathogenesis and treatment of psoriasis. J Drugs Dermatol JDD. 2002;1(3):264-275.
  21. Delgado M, Ganea D. Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions. Amino Acids. 2013;45(1):25-39. doi:10.1007/s00726-011-1184-8
  22. Pozo D, Delgado M, Martínez M, et al. Immunobiology of vasoactive intestinal peptide (VIP). Immunol Today. 2000;21(1):7-11. doi:10.1016/s0167-5699(99)01525-x
  23. Abad C, Niewiadomski P, Loh DW, Waschek J. Neurotransmitter and immunomodulatory actions of VIP and PACAP: lessons from knockout mice. Int J Pept Res Ther. 2006;(12):297-310.
  24. Gomariz RP, Martinez C, Abad C, Leceta J, Delgado M. Immunology of VIP: a review and therapeutical perspectives. Curr Pharm Des. 2001;7(2):89-111. doi:10.2174/1381612013398374
  25. Korkmaz OT, Tunçel N, Tunçel M, Oncü EM, Sahintürk V, Celik M. Vasoactive intestinal peptide (VIP) treatment of Parkinsonian rats increases thalamic gamma-aminobutyric acid (GABA) levels and alters the release of nerve growth factor (NGF) by mast cells. J Mol Neurosci MN. 2010;41(2):278-287. doi:10.1007/s12031-009-9307-3
  26. Lundberg P, Lie A, Bjurholm A, et al. Vasoactive intestinal peptide regulates osteoclast activity via specific
  27. binding sites on both osteoclasts and osteoblasts. Bone. 2000;27(6):803-810. doi:10.1016/s8756-3282(00)00394-x
  28. Delgado M, Ganea D. Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson’s disease by blocking microglial activation. FASEB J Off Publ Fed Am Soc Exp Biol. 2003;17(8):944-946. doi:10.1096/fj.02-0799fje
  29. Vacas E, Bajo AM, Schally AV, Sánchez-Chapado M, Prieto JC, Carmena MJ. Antioxidant activity of vasoactive intestinal peptide in HK2 human renal cells. Peptides. 2012;38(2):275-281. doi:10.1016/j.peptides.2012.09.011
  30. Silness J, Löe H. Periodontal disease in pregnancy II. Correlation between oral hygiene and periodontal condition. Acta Odontol Scand. 1964;22(1):121-135.
  31. Löe H, Silness J. Periodontal disease in pregnancy I. Prevalence and severity. Acta Odontol Scand. 1963;21(6):533-551.
  32. Listgarten MA. Periodontal probing: what does it mean? J Clin Periodontol. 1980;7(3):165-176. doi:10.1111/j.1600- 051x.1980.tb01960.x
  33. Sterio DC. The unbiased estimation of number and sizes of arbitrary particles using the disector. J Microsc. 1984;134(2):127-136.
  34. Glaser J, Greene G, Hendricks S. Stereology for Biological Research: With a Focus on Neuroscience. mbf Press; 2007.
  35. Gundersen HJG, Jensen EB. The efficiency of systematic sampling in stereology and its prediction. J Microsc. 1987;147(3):229-263.
  36. Howard V, Reid S, Baddeley A, Boyde A. Unbiased estimation of particle density in the tandem scanning reflected light microscope. J Microsc. 1985;138(Pt 2):203- 212. doi:10.1111/j.1365-2818.1985.tb02613.x
  37. Luthman J, Friskopp J, Dahllöf G, Ahlström U, Sjöström L, Johansson O. Immunohistochemical study of neurochemical markers in gingiva obtained from periodontitisaffected sites. J Periodontal Res. 1989;24(4):267-278. doi:10.1111/j.1600-0765.1989.tb01792.x
  38. Linden GJ, Mullally BH, Burden DJ, et al. Changes in vasoactive intestinal peptide in gingival crevicular fluid in response to periodontal treatment. J Clin Periodontol. 2002;29(6):484-489. doi:10.1034/j.1600- 051x.2002.290602.x
  39. Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. J Immunol Baltim Md 1950. 1999;162(3):1707-1716.
  40. Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D. VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNgamma synthesis by T cells. J Neuroimmunol. 1999;96(2):167-181. doi:10.1016/s0165-5728(99)00023-5
  41. Ganea D, Delgado M. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity. Crit Rev Oral Biol Med Off Publ Am Assoc Oral Biol. 2002;13(3):229-237. doi:10.1177/154411130201300303
  42. Delgado M, Pozo D, Martinez C, et al. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNF-alpha production by macrophages: in vitro and in vivo studies. J Immunol Baltim Md 1950. 1999;162(4):2358-2367.
  43. Miotto D, Boschetto P, Bononi I, et al. Vasoactive intestinal peptide receptors in the airways of smokers with chronic bronchitis. Eur Respir J. 2004;24(6):958-963. doi:10.1183/ 09031936.04.10031504
  44. Boström L, Linder LE, Bergström J. Smoking and crevicular fluid levels of IL-6 and TNF-alpha in periodontal disease. J Clin Periodontol. 1999;26(6):352-357. doi:10.1034/j.1600- 051x.1999.260604.x